DNDi E-news
April 2014   |   View Online
Silvia Gold

Viewpoint by Silvia Gold, President Mundo Sano Foundation

Global Alliance for the Treatment of Chagas Disease:
Thinking About the Patients

American Trypanosomiasis, more commonly known as Chagas disease, no longer reflects the geographical scope of the disease. Today, Chagas disease affects people around the world. It is hard to imagine that a disease, discovered over a century ago, which today can be easily diagnosed and for which effective treatment exists, continues to be a problem of severe health impact. »

Sharing Data to Promote R&D for Neglected Diseases

Research on neglected diseasesA recent publication in Lancet Global Health by DNDi and colleagues showed that from 2000 to 2011 only 4% of all new drugs and vaccines approved were for neglected diseases. The data sets compiled for this analysis are now available open access. »

DNDi report on Paediatric HIV Roundtable with Industry

Mother with HIV positive babyA Paediatric HIV Roundtable with Industry was hosted by DNDi in Dakar, Senegal, late last year, resulting in a call to action to expedite development of paediatric ARV formulations. The report also provides a snapshot of all paediatric ARVs developed or in development today.

Award for Sanofi-DNDi Partnership

Sanofi-DNDi partnership receives awardSanofi and DNDi have received the 2014 Corporate Social Responsibility Alliance Excellence Award from ASAP in recognition of the “profound, measurable, and positive social impact” that the decade-long public-private partnership has had in the fight against malaria. »

Read the LEAP Newsletter!

LEAP Newsletter Issue 2 - Cover pageThis 2nd edition of the Leishmaniasis East Africa Platform (LEAP) Newsletter provides insights into drug regulation in Kenya, capacity building, clinical trial updates, developments in the field of diagnostics for kala azar in Africa, and introduces the notion of good financial practices. »


JAIDS: The pharmacokinetics and acceptability of lopinavir/ritonavir minitab sprinkles, tablets and syrups in African HIV-infected children »

Malaria Journal: Plasmodium falciparum clearance in clinical studies of artesunate-amodiaquine and comparator treatments in sub-Saharan Africa, 1999–2009 »

Clinical Pharmacokinetics: Determination of an optimal dosing regimen for fexinidazole, a novel oral drug for the treatment of human African trypanosomiasis: first-in-human studies »

Malaria Journal: Communicating the AMFm message: effect of communication & training on private for-profit provider awareness and knowledge multi-country anti-malarial subsidy intervention »
Punto de Vista: Silvia Gold »
Primer análisis del impacto del modelo de DNDi »

Ponto de Vista: Silvia Gold »
Primeira análise do impacto do modelo da DNDi »

London, 15 May 2014

Follow us on social media:
Twitter Facebook LinkedIn YouTube
Visit our websites:
DNDi.org  DNDiAL.org  DNDiNA.org  DNDiJapan.org  
Copyright © 2014 Drugs for Neglected Diseases initiative (DNDi), All rights reserved.
You are receiving this email because you are part of DNDi's network. You have the option to unsubscribe.

Our mailing address is:
Drugs for Neglected Diseases initiative (DNDi)
15 ch. Louis-Dunant
Geneva 1202

Add us to your address book

unsubscribe from this list    update subscription preferences